The funding will be used to develop Raremark’s patient-engagement and data-analysis technology.
Hazy is an AI spin-out from UCL and is one of the businesses invested in by the UCL Technology Fund which is managed by Albion in collaboration with UCLB.
The judges looked for a track record of fundraising between April 2017 – April 2018 An impressive level of investment and exits achieved during the period A reputation for providing valuable strategic and commercial advice to portfolio companies A strong financial return for private investors
The company’s insulin and glucagon products, which are set to transform diabetes treatments, could have peak annual sales of between $200 million and $1 billion each.
Their mission is to connect healthcare systems around the world, making communication secure, transparent and flexible for healthcare professionals and patients.
Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies
Hazy offers a unique platform that allows businesses to share data responsibly and securely through a workflow tool, automatically anonymises and adapting to changing datasets.